Savara Inc.
savarapharma.comWhat Do They Do?
Develops MOLBREEVI, an inhaled biologic treatment for autoimmune pulmonary alveolar proteinosis, a rare lung disease.
10-K for FY2025, filed Mar 13, 2026
Sources
How Are They Changing?
Since the FY2025 annual report
Latest quarter: Q2 FY2026, the three months to Jun 30, 2026
- Net income
-
Sources
10-Q for Q2 FY2026, filed Aug 11, 2026
−$40.2MView ↗
- ▲ +32% (Loss)
- vs −$30.4M in Q2 FY2025
-
Jun 8, 2026
Robert Lutz appointed chief financial and operating officer
He will take the role effective July 15, 2026, following David Lowrance’s resignation for health reasons.
Sources
8-K, filed Jun 8, 2026
On June 5, 2026, the Board appointed Robert Lutz to become the Chief Financial and Operating Officer of Savara effective July 15, 2026 (the…View ↗
Who Do They Compete With?
Competes with Nobelpharma and Partner Therapeutics
10-K for FY2025, filed Mar 13, 2026
Sources
A glycosylated GM-CSF product, sargramostim (Leukine), available in the U.S., is approved for intravenous or subcutaneous delivery in…View ↗
Loading...
Comments
